ixbiopharma
it's life changing
(Co. Reg. No: 200405621W)

NEWS RELEASE

Warrant Exercises Reach 92% as Management and Directors Lead Strong Insider Participation

Key Highlights

- ✓ 92% of warrants exercised as at 15 July 2026, converting into approximately 53 million new shares
- ✓ Management and directors account for approximately 24.2 million shares, or 46% of all warrants exercised, a strong signal of insider conviction
- ✓ Broad-based conversion reflects shareholder confidence since the 2024 rights cum warrants issue
- ✓ Proceeds strengthen the balance sheet and support U.S. expansion via the compounding pharmacy pathway

Singapore, 15 July 2026 – iX Biopharma Ltd. ("the **Company**") is pleased to announce strong momentum in the exercise of its warrants. As at 15 July 2026, 92% of the warrants issued under the Company's 2024 rights cum warrants issue have been exercised, converting into approximately 53 million new shares. Notably, the Company's management and directors account for approximately 24.2 million of these shares, or 46% of all warrants exercised, a substantial vote of insider confidence led by Chairman & CEO Eddy Lee.

The strong conversion follows a significant appreciation in the Company's share price since the 2024 rights cum warrants issue, and has enabled the Company to realise the substantial majority of the potential gross proceeds of up to S$3.45 million. These proceeds strengthen the Company's balance sheet and support its growth priorities, including its expansion into the United States market via the compounding pharmacy pathway. The Company remains focused on delivering sustainable value for shareholders.

Contact for media:

Eva Tan	Alex Tan
Chief Commercial Officer	8PR
T: +65 6235 3212	T: +65 9451 5252
E: eva.tan@ixbiopharma.com	E: alex.tan@8prasia.com